(CercleFinance.com) – Parvus Asset Management Europe Limited, acting on behalf of clients and funds, told the AMF that it exceeded the threshold of 5% of Ipsen’s capital on December 21 and held 5.01 % of the capital and 3.18% of the voting rights of this pharmaceutical company.
This threshold crossing results from an acquisition of Ipsen shares on the market. The declarant specified that he held 4,199,384 shares under ‘equity swap’ contracts with cash settlement, exercisable until October 3, 2022.